Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71:209–49.
Britt KL, Cuzick J, Phillips KA. Key steps for effective breast cancer prevention. Nat Rev Cancer. 2020;20:417–36.
Article CAS PubMed Google Scholar
Kashyap D, Pal D, Sharma R, Garg VK, Goel N, Koundal D, Zaguia A, Koundal S, Belay A. Global Increase in Breast Cancer Incidence: Risk Factors and Preventive Measures. Biomed Res Int. 2022;2022:9605439.
Katsura C, Ogunmwonyi I, Kankam HK, Saha S. Breast cancer: presentation, investigation and management. Br J Hosp Med (Lond). 2022;83:1–7.
Wilkinson L, Gathani T. Understanding breast cancer as a global health concern. Br J Radiol. 2022;95:20211033.
Lin W, Zhou Q, Wang CQ, et al. LncRNAs regulate metabolism in cancer. Int J Biological Sciences. 2020;16:1194–206.
Sideris N, Dama P, Bayraktar S, et al. LncRNAs in breast cancer: a link to future approaches. Cancer Gene Ther. 2022;29:1866–77.
Article CAS PubMed PubMed Central Google Scholar
Han JJ, Wang XQ, Zhang XA. Functional Interactions Between lncRNAs/circRNAs and miRNAs: Insights Into Rheumatoid Arthritis. Frontiers Immunol. 2022;13:1–17.
Venkatesh J, Wasson MD, Brown JM, et al. LncRNA-miRNA axes in breast cancer: Novel points of interaction for strategic attack. Cancer letters. 2021;509:81–8.
Article CAS PubMed Google Scholar
Ghafouri-Fard S, Glassy MC, Abak A, et al. The interaction between miRNAs/lncRNAs and Notch pathway in human disorders. Biomedicine Pharmacotherapy Biomedecine Pharmacotherapie. 2021;138:1–14.
Shi Y, Yang D, Qin Y. Identifying prognostic lncRNAs based on a ceRNA regulatory network in laryngeal squamous cell carcinoma. BMC Cancer. 2021;21:705.
Article CAS PubMed PubMed Central Google Scholar
Ye J, Li H, Wei J, Luo Y, Liu H, Zhang J, Luo X. Risk Scoring System based on lncRNA Expression for Predicting Survival in Hepatocellular Carcinoma with Cirrhosis. Asian Pac J Cancer Prev. 2020;21:1787–95.
Article CAS PubMed PubMed Central Google Scholar
Wilson K, Shiuan E, Brantley-Sieders DM. Oncogenic functions and therapeutic targeting of EphA2 in cancer. Oncogene. 2021;40:2483–95.
Article CAS PubMed PubMed Central Google Scholar
Zhao P, Jiang D, Huang Y, et al. EphA2: A promising therapeutic target in breast cancer. J Genet Genomics. 2021;48:261–7.
Article CAS PubMed Google Scholar
Zaghlool A, Niazi A, Björklund ÅK, et al. Characterization of the nuclear and cytosolic transcriptomes in human brain tissue reveals new insights into the subcellular distribution of RNA transcripts. Scientific reports. 2021;11:1–14.
Li W, Ye K, Li X, Liu X, Peng M, Chen F, Xiong W, Wang Y, Zhu L. YTHDC1 is downregulated by the YY1/HDAC2 complex and controls the sensitivity of ccRCC to sunitinib by targeting the ANXA1-MAPK pathway. J Exp Clin Cancer Res. 2022;41:250.
Article CAS PubMed PubMed Central Google Scholar
Zeng C, Yuan G, Hu Y, et al. Repressing phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma by microRNA-142-3p restrains the progression of hepatocellular carcinoma. Bioengineered. 2022;13:1491–506.
Article CAS PubMed PubMed Central Google Scholar
Müller K, Ogris M, Sami H. Firefly Luciferase-Based Reporter Gene Assay for Investigating Nanoparticle-Mediated Nucleic Acid Delivery. Methods Mol Biol. 2019;1943:227–39.
Liu J, Xue N, Guo Y, et al. CircRNA_100367 regulated the radiation sensitivity of esophageal squamous cell carcinomas through miR-217/Wnt3 pathway. Aging. 2019;11:12412–27.
Article CAS PubMed PubMed Central Google Scholar
Jiang X, Wang G, Liu Y, et al. A novel long non-coding RNA RP11–286H15.1 represses hepatocellular carcinoma progression by promoting ubiquitination of PABPC4. Cancer letters. 2021;499:109–21.
Article CAS PubMed Google Scholar
Shakeri A, Hafezian T, Kúsz N, et al. Cytotoxicity, apoptosis inducing activity and Western blot analysis of tanshinone derivatives from Stachys parviflora on prostate and breast cancer cells. Molecular Biology Reports. 2022;49:8251–8.
Article CAS PubMed Google Scholar
Okuyama T, Sakamoto R, Kumagai K, et al. EPHA2 antisense RNA modulates EPHA2 mRNA levels in basal-like/triple-negative breast cancer cells. Biochimie. 2020;179:169–80.
Article CAS PubMed Google Scholar
Xiao, T., Xiao, Y., Wang, W., et al. (2020) Targeting EphA2 in cancer. Journal of hematology & oncology13, 1–17
Najafi S, Khatami SH, Khorsand M, et al. Long non-coding RNAs (lncRNAs); roles in tumorigenesis and potentials as biomarkers in cancer diagnosis. Experimen Cell Res. 2022;418:1–13.
Han X, Mo J, Yang Y, et al. Crucial Roles of LncRNAs-Mediated Autophagy in Breast Cancer. Int J Medical Scie. 2022;19:1082–92.
Shen Y, Peng X, Shen C. Identification and validation of immune-related lncRNA prognostic signature for breast cancer. Genomics. 2020;112:2640–6.
Article CAS PubMed Google Scholar
Li N, Su M, Zhu L, Wang L, Peng Y, Dong B, Ma L, Liu Y. A Prognostic Signature of Glycolysis-Related Long Noncoding RNAs for Molecular Subtypes in the Tumor Immune Microenvironment of Lung Adenocarcinoma. Int J Gen Med. 2021;14:8955–74.
Article CAS PubMed PubMed Central Google Scholar
Lamb CA, Vanzulli SI, Lanari C. Hormone receptors in breast cancer: more than estrogen receptors. Medicina. 2019;79:540–5.
Nagaraj G, Ma CX. Clinical challenges in the management of hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer: a literature review. Advances in therapy. 2021;38:109–36.
Article CAS PubMed Google Scholar
Saw PE, Xu X, Chen J, et al. Non-coding RNAs: the new central dogma of cancer biology. Scie China Life Scie. 2021;64:22–50.
Yan H, Bu P. Non-coding RNA in cancer. Essays Biochem. 2021;65:625–39.
Article CAS PubMed PubMed Central Google Scholar
Toden S, Zumwalt TJ, Goel A. Non-coding RNAs and potential therapeutic targeting in cancer. Biochimica et biophysica acta. Reviews Cancer. 2021;1875:1–18.
Murata M, Marugame Y, Morozumi M, Murata K, Kumazoe M, Fujimura Y, Tachibana H. (-)-Epigallocatechin-3-O-gallate upregulates the expression levels of miR-6757-3p, a suppressor of fibrosis-related gene expression, in extracellular vesicles derived from human umbilical vein endothelial cells. Biomed Rep. 2023;18:19.
Article CAS PubMed PubMed Central Google Scholar
Gao Z, Han X, Zhu Y, Zhang H, Tian R, Wang Z, Cui Y, Wang Z, Niu R, Zhang F. Drug-resistant cancer cell-derived exosomal EphA2 promotes breast cancer metastasis via the EphA2-Ephrin A1 reverse signaling. Cell Death Dis. 2021;12:414.
Article CAS PubMed PubMed Central Google Scholar
Liu X, Li Y, Chen C, et al. Exosomal EphA2 promotes tumor metastasis of triple-negative breast cancer by damaging endothelial barrier. Clinical Experimen Metastasis. 2023;40:105–16.
Zhou L, Lu X, Zhang B, et al. EphA2 as a new target for breast cancer and its potential clinical application. Intern J Clinical Experimen Pathology. 2021;14:484–92.
Han B, Zhang H, Tian R, et al. Exosomal EPHA2 derived from highly metastatic breast cancer cells promotes angiogenesis by activating the AMPK signaling pathway through Ephrin A1-EPHA2 forward signaling. Theranostics. 2022;12:4127–46.
Article CAS PubMed PubMed Central Google Scholar
Dai T, Liu Y, Cao R, et al. CBX7 regulates metastasis of basal-like breast cancer through Twist1/EphA2 pathway. Translational oncology. 2022;24:1–12.
Psilopatis I, Souferi-Chronopoulou E, Vrettou K, Troungos C, Theocharis S. EPH/Ephrin-Targeting Treatment in Breast Cancer: A New Chapter in Breast Cancer Therapy. Int J Mol Sci. 2022;23:15275.
Comments (0)